Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
BioNTech SE ADR rises Friday, still underperforms market | news.google.com • |
BioNTech SE ADR falls Thursday, underperforms market | news.google.com • |
BioNTech SE ADR falls Thursday, underperforms market | news.google.com • |
What's Going On With Pfizer Stock On Thursday?- Benzinga | news.google.com • |
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology | reuters.com • |
BioNTech SE ADR falls Wednesday, underperforms market | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.41 | N/A | N/A | N/A |
2024-03-20 | 2023-12 | 2.64 | 2.05 | -0.59 | -22.35% |
2023-11-06 | 2023-09 | -0.53 | 0.73 | 1.26 | 237.74% |
2023-11-06 | 2023-09 | -0.53 | N/A | N/A | N/A |
2023-08-07 | 2023-06 | -0.75 | -0.86 | -0.11 | -14.67% |
2023-08-07 | 2023-06 | -0.75 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-16 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-15 | HSBC | Downgrade | Buy | Hold |
2023-08-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-07 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-07-31 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Baillie Gifford and Company | 7.45M | 804.11M | 3.11% |
2023-06-29 | Primecap Management Company | 4.66M | 502.94M | 1.94% |
2023-06-29 | Temasek Holdings (Private) Limited | 4.52M | 487.64M | 1.88% |
2023-06-29 | Flossbach von Storch AG | 3.44M | 371.47M | 1.44% |
2023-06-29 | Artisan Partners Limited Partnership | 2.03M | 219.13M | 0.85% |
2023-06-29 | Blackrock Inc. | 1.73M | 186.84M | 0.72% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 2.23M | 241.18M | 0.93% |
2023-07-30 | Primecap Odyssey Aggressive Growth Fund | 1.37M | 149.11M | 0.57% |
2023-08-30 | iShares NASDAQ Biotechnology ETF | 1.37M | 165.80M | 0.57% |
2023-09-29 | New Perspective Fund Inc | 800.00K | 86.91M | 0.33% |
2023-09-29 | First Trust NYSE Arca Biotechnology Index Fund | 416.94K | 45.30M | 0.17% |
2023-06-29 | Artisan Mid-Cap Fund | 375.33K | 40.51M | 0.16% |
Dividend | Date |
---|---|
2.111 | 2022-06-02 |
-
There is no fathomable reason for $BNTX valuation to be only 62% that of $MRNA. BionTech might be splitting its revenue with Pfizer/ Fosun but it is also selling 4 times Moderna. Half of 4x revenue is still 2x revenue. At minimum $BNTX should have the same market cap as $MRNA. That means it’s stock should be 1.5x present levels, around $350, just to have the same valuation as Moderna. Huge upside sitting here with minimal risk.
-
Dip mean buy chance? lmao
-
It seems overvalued
-
It seems overvalued
-
No one steals your stocks. They are all on the market. Cut this crap! But if you dare to
-
It surely overpriced. Time to sell
-
When the price tumbles, some idiot would say why people sell for a potentially few hundred worth stock lol
-
Party is over
-
-
-
$BNTX is being held back by weak-hearted, “clay-handed” investors who simply don’t have enough belief to hold on to their shares despite all the fantastic news and great numbers being reported by the company. They keep selling, either taking profit on small upticks or panic-selling on the slightest negative news. If only $BNTX shareholders had “diamond-hands” like the punters driving $GME up for no rhyme or reason! Even the level of belief that $NVAX buyers are showing despite no actual vaccine being in the market would be sufficient to drive $BNTX to the moon. And there is simply no reason why $MRNA should have a market valuation that is 1.5x $BNTX. Parity with $MRNA itself should drive the price to $300+.
-
It is expected with good earning for Q1. It is not catalyst anymore
-
Biden this retarded dementia old man just want to ruin everything. Why would people vote for this sucker
-
-
-
-
-
$BNTX
Av Est. EPS: $32.07 (‘21) and $18.69 (‘22)
Av Est. Revenue: $12.29B (‘21) and $7.73B (‘22)
Market Cap @ SP 180: $42.3B
P/E @ SP 180: 9.63 (based on ‘22 EPS)$MRNA
Av Est. EPS: $23.27 (‘21) and $16.58 (‘22)
Av Est. Revenue: $17.46B (‘21) and $13.69B (‘22)
Market Cap @ SP 180: $72.2B
P/E @ SP 180: 10.88 (based on ‘22 EPS)Looks like market is grossly underestimating revenue & EPS for $BNTX. Once revenue and EPS for this and next year for $BNTX becomes clear there will be a major price correction. If $BNTX has higher revenue and higher earnings it should have a higher market cap, so price should be more than 2x that of $MRNA.
-
BioNTech SE ADR rises Friday, still underperforms market
news.google.com • -
BioNTech SE ADR falls Thursday, underperforms market
news.google.com • -
BioNTech SE ADR falls Thursday, underperforms market
news.google.com • -
What's Going On With Pfizer Stock On Thursday?- Benzinga
news.google.com • -
BioNTech SE ADR falls Wednesday, underperforms market
news.google.com • -
BioNTech SE ADR rises Tuesday, still underperforms market
news.google.com • -
Is BioNTech (BNTX) Stock Undervalued Right Now?
news.google.com • -
BioNTech SE ADR rises Monday, outperforms market
news.google.com • -
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
news.google.com • -
BioNTech (BNTX) Soars: Stock Adds 5.2% in Session
news.google.com • -
The 3 Best Bargain Stocks to Buy in Q2 2024
investorplace.com • -
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
investorplace.com • -
BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
seekingalpha.com • -
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
investorplace.com • -
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
investorplace.com • -
It's Time! 3 Dodgy Pharma Stocks to Sell in February
investorplace.com • -
3 Pharma Stocks to Sell in February Before They Crash and Burn
investorplace.com • -
Top 10 stocks to buy in 2024
invezz.com • -
BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
seekingalpha.com • -
BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
seekingalpha.com • -
Barron's Favorite 10 Stocks for 2024
barrons.com • -
BioNTech Vs. Moderna: Navigating The mRNA Landscape
seekingalpha.com • -
3 Biotech Stocks You'll Regret Not Buying Soon: November 2023
investorplace.com • -
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
investorplace.com • -
BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript
seekingalpha.com • -
Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move
proactiveinvestors.com • -
BioNTech slashes revenue outlook amid lower Covid vaccine sales
proactiveinvestors.com • -
7 Undervalued Stocks That Analysts Love Right Now
investorplace.com • -
Is BioNTech Stock a Buy Now?
fool.com • -
7 Stocks That Are Heading for a Train Wreck
investorplace.com • -
Pfizer and BioNtech take big write-downs on Covid jab stocks
proactiveinvestors.co.uk • -
7 Innovator Stocks Primed for Exceptional Growth
investorplace.com • -
German court suspends mRNA patent trial against BioNTech
reuters.com • -
US FDA authorizes updated COVID vaccines
reuters.com • -
3 Stocks to Buy For the COVID Resurgence
marketbeat.com • -
UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging
proactiveinvestors.co.uk • -
BioNTech: Not Just Another Jab In The Arm
seekingalpha.com • -
Covid Hospitalizations Jump. So Could Vaccine Demand.
barrons.com • -
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
investorplace.com • -
Why BioNTech Stock Was Sinking Today
fool.com • -
BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioNTech Revenue Plunges on Falling Demand for COVID-19 Vaccines
investopedia.com • -
Biotech Stock Hits 2-Year Low as Vaccine Sales Decline
schaeffersresearch.com • -
BioNTech stock declines as revenue topples on lower demand for Covid vaccine
proactiveinvestors.com • -
Disney, UPS, and More Stocks to Watch This Week
barrons.com • -
BioNTech: Unraveling A Bargain, A Hidden Opportunity In Market Misjudgments
seekingalpha.com • -
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
investorplace.com • -
New Strong Buy Stocks for July 11th
zacks.com • -
3 Ugly Stocks That Actually Hide Beautiful Potential
investorplace.com • -
Why Shares of BioNTech Rose Friday
fool.com • -
7 Deeply Undervalued Growth Stocks to Buy in June
investorplace.com •